27-Apr-2026
Sagimet Biosciences Appoints Former Omeros CMO Andreas Grauer to Strengthen Clinical Leadership
Market Chameleon (Mon, 20-Apr 3:09 AM ET)
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
Globe Newswire (Mon, 20-Apr 7:00 AM ET)
Market Chameleon (Thu, 16-Apr 5:24 AM ET)
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA (narsoplimab-wuug)
Business Wire (Thu, 16-Apr 8:45 AM ET)
Novo Nordisk Deal Transforms Omeros Financials as YARTEMLEA Launch Gains Traction
Market Chameleon (Wed, 1-Apr 3:31 AM ET)
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
Business Wire (Tue, 31-Mar 4:02 PM ET)
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
Business Wire (Thu, 26-Mar 8:45 AM ET)
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
Business Wire (Sat, 21-Mar 3:23 AM ET)
Omeros Announces Successful Primate Study in OncotoX-AML Drug Program
Business Wire (Tue, 17-Feb 8:45 AM ET)
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
Omeros trades on the NASDAQ stock market under the symbol OMER.
As of April 27, 2026, OMER stock price climbed to $14.74 with 1,818,049 million shares trading.
OMER has a beta of 0.53, meaning it tends to be less sensitive to market movements. OMER has a correlation of 0.00 to the broad based SPY ETF.
OMER has a market cap of $1.05 billion. This is considered a Small Cap stock.
Last quarter Omeros reported $0 in Revenue and $3.14 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $3.15.
In the last 3 years, OMER traded as high as $17.65 and as low as $.92.
The top ETF exchange traded funds that OMER belongs to (by Net Assets): VTI, IWM, VXF, XPH, IWO.
OMER has outperformed the market in the last year with a price return of +101.6% while the SPY ETF gained +31.2%. OMER has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +16.3% and +29.5%, respectively, while the SPY returned +3.1% and +4.2%, respectively.
OMER support price is $12.96 and resistance is $14.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OMER shares will trade within this expected range on the day.
